Skip to main content

Table 1 Characteristics of the study subjects (BCIS and controls)

From: Genetic risk variants associated with in situ breast cancer

 

CPS-II

EPIC

MEC

NHS

PLCO

Total

 

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Number

3048

569

4745

19

1724

74

3630

489

859

166

14,006

1317

Ductal

 

297 (52 %)

 

14 (74 %)

   

367 (75 %)

 

114 (69 %)

 

792 (62 %)

Lobular

 

42 (8 %)

 

2 (10 %)

   

82 (17 %)

 

15 (9 %)

 

141 (11 %)

Unknown/other

 

230 (40 %)

 

3 (16 %)

 

74 (100 %)

 

40 (8 %)

 

37 (22 %)

 

384 (29 %)

White

3048

569

4745

19

574

15

3605

467

859

166

12,831

1236

Hispanic

.

.

.

.

292

10

2

.

.

.

294

10

African American

.

.

.

.

230

9

7

11

.

.

237

20

Asian

.

.

.

.

379

23

7

6

.

.

386

29

Hawaiian

.

.

.

.

249

17

.

.

.

.

249

17

Other

.

.

.

.

.

.

9

5

.

.

9

5

Age at diagnosis/recruitment, mean (sd)

61.9 (6.2)

68.81 (6.87)

54.0 (8.0)

61.16 (7.32)

57.0 (8.4)

62.86 (8.00)

57.1 (10.7)

59.04 (10.2)

62.3 (5.0)

66.13 (5.54)

57.4 (8.9)

64.41 (9.31)

ER positive

.

151

.

4

.

10

.

175

.

32

.

372

ER negative

.

22

.

.

.

2

.

35

.

9

.

68

ER not classified

.

396

.

15

.

58

.

26

.

.

.

495

ER not classified

.

.

.

.

.

4

.

253

.

125

.

382

BMI (kg/m2), mean (sd)

25.60 (4.93)

25.50 (4.82)

25.44 (4.31)

23.47 (3.57)

26.85 (6.16)

27.54 (5.68)

25.85 (5.20)

25.61 (5.12)

27.08 (5.38)

27.76 (5.47)

25.90 (5.05)

25.91 (5.12)

Height (m), mean (sd)

1.64 (0.063)

1.64 (0.065)

1.62 (0.066)

1.61 (0.054)

1.61 (0.070)

1.59 (0.069)

1.64 (0.061)

1.64 (0.064)

1.63 (0.063)

1.63 (0.067)

1.63 (0.066)

1.64 (0.066)

Premenopausal

108

34

1134

3

357

14

1046

172

.

.

2645

223

Postmenopausal

2902

527

2883

13

1307

56

2473

305

852

165

10,417

1066

Perimenopausal

38

8

728

3

60

4

111

12

7

1

944

28

  1. CPS-II Cancer Prevention Study II, EPIC European Prospective Investigation into Cancer, MEC Multiethnic Cohort, NHS Nurses’ Health Study, PLCO Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, sd standard deviation, ER estrogen receptor, BMI body mass index